Abstract. It is difficult to distinguish benign from malignant follicular thyroid tumors by histological or cytological examination. The goal of this study was to reveal gene expression variations between benign and malignant follicular lesions of the thyroid gland. We investigated gene expression profiles from 24 follicular thyroid tumors (12 carcinomas and 12 adenomas) and 13 normal thyroid tissues using high-density human cDNA arrays. The identification of gene expression changes was based on signal intensity ratios of tumor versus normal thyroid parenchyma. Expression patterns of a set of known genes were found to be significantly different between follicular adenomas and follicular carcinomas. Our results demonstrate a potential use of gene expression profiling for differentiating benign from malignant follicular thyroid tumors. A detailed investigation of the differentially expressed genes could give new insights into molecular pathways of malignant transformation of thyroid follicular neoplasm and may help to develop a molecular tool for the preoperative differential diagnosis.
Introduction
Thyroid carcinoma is the most common endocrine malignancy, accounting for 90% of all neuroendocrine malignancies and 1% of all malignant diseases (1, 2) . It is estimated that 5-10% of the population will develop a clinically significant thyroid nodule during their lifetime (3) . Since the majority of thyroid nodules are benign, a major concern is to preoperatively differentiate between the benign and malignant thyroid lesions.
Currently, the best diagnostic approach for such a preoperative evaluation is a fine needle aspiration (FNA) biopsy, which has greatly decreased the number of surgical intervention required for a thyroid nodule since it was introduced in 1970s (4) . The diagnosis of papillary thyroid carcinoma is usually straightforward on FNA cytological examination, with a reliability of 95% (3, 5) . However, FNA cytology cannot discriminate between benign and malignant thyroid tumors with follicular growth features. Follicular thyroid adenoma (FTA) and follicular thyroid carcinoma (FTC) are often grouped together as indeterminate or suspicious thyroid lesions, which usually undergo hemithyroidectomy to look for invasion through the tumor capsule or the blood vessels. Accordingly, only ~20% of these indeterminate FNAs prove to be malignant (6) (7) (8) (9) . A postoperative diagnosis of malignancy leads to a second-stage complete thyroidectomy. This twostage surgery has higher morbidity than initial total thyroidectomy. On the other hand, total thyroidectomy for all patients with suspicious thyroid lesions would result in many patients undergoing an unnecessary surgical procedure and requiring lifelong thyroid hormone replacement. Still, it is often difficult to achieve a clear cut histologic differentiation between FTA and FTC, which depends on tumor capsular penetration and vascular invasion. Thus, there is a clear need to search for molecular markers as ancillary tools for improving the preoperative diagnosis.
To date, no specific molecular markers have proved to be of practical diagnostic value for discriminating between benign and malignant follicular tumors, though many genetic alterations have been related to thyroid cancer. Among the genetic abnormalities, the PAX8-PPARG rearrangement and overexpression of galectin-3 (encoded by LGALS3) were initially reported to be promising markers for the differential diagnosis (10) (11) (12) . However, other subsequent studies have shown that these molecules are also involved in benign lesions such as multinodular goiter and FTA (13) (14) (15) (16) (17) . Gene expression profiling based on gene array technology has been used to characterize follicular thyroid tumors (18) (19) (20) (21) (22) (23) RNA preparation, hybridization and data generation. Extraction of total RNA, reverse transcription and hybridization were performed as previously described (25) . Customer-designed cDNA filters that contain about 4,300 sequence-verified human cDNA clones, spotted in duplicate, were obtained from the Resource Center of the German Human Genome Project (RZPD; www.rzpd.de). The visualization of hybridization signals and signal normalization were conducted as described elsewhere (25) . Signal intensity ratios of tumor versus the median of the 13 normal thyroid samples were calculated for each target on the array.
Data analysis. The GeneSight software (BioDiscovery, Inc., Los Angeles) was used for ratio calculation, hierarchical and k-means clustering, principal component analysis (PCA) and statistical analyses. On the basis of gene expression ratios of tumor versus normal samples, fold change analysis was conducted to detect genes with 2-fold or greater change. The fold change value was used to define the gene expression level. A gene that had a ratio value of ≥2 was considered to be up-regulated, whereas one with a ratio of ≤0.5 was regarded as down-regulated. The gene expression profiles between the 2 tumor groups were statistically analyzed with the Student's t-test, assuming unequal variance, with a false discovery rate of 1% (P-value of <0.01) to produce a list of genes with differential expression. Hierarchical cluster analysis was performed for the differentially expressed genes to assess and illustrate a genetic similarity. The discriminative power of the selected genes was then evaluated through k-means cluster analyses in a leaveone-out procedure (LOOP), in which one sample at a time was held out. A permutation test was performed to verify the significance level for each gene by comparing its statistic to the permutation distribution of the tumor samples that were randomly divided into two groups. Three-dimensional PCA mapping was used to explore distributions of the examined samples on the basis of a set of selected genes. In PCA, the examined samples are represented by points in a threedimensional space. The distance between any pair of points is related to the similarity between the two samples in highdimensional space. Samples that are near each other are similar in gene expression profile and conversely, the ones that are far apart are different in expression pattern.
Results
Frequently de-regulated genes. After calculating the ratios of tumor versus the median value of normal thyroid specimens for each gene, we conducted fold change analysis to determine the most frequently de-regulated genes. The frequency of genes with at least a 2-fold alteration in thyroid tumors were assessed and summarized in Table I . No known gene was found to display a 2-fold or greater change in all follicular carcinomas or all follicular adenomas. Compared with adenomas, carcinomas showed more genes under-expressed and less genes over-expressed. The most frequently deregulated genes, namely genes with ≥2-fold alteration detected in >8 adenomas or carcinomas, are shown in Table II .
Distinct gene expression profiles of the two tumor groups.
Statistical significance in expression difference was determined by the Student's t-test for all 4,300 sequenceverified genes between the two tumor groups. Genes (304) that displayed differences at the significance level of P<0.01 underwent cluster analyses. We conducted a two-way hierarchical cluster analysis of the 24 tumors across the 304 genes. Tumors were segregated into two main histologyassociated groups, one group comprising all adenomas and the other including all carcinomas (Fig. 1A) . The 304 genes comprise of 131 known and 173 unknown genes. Since it is of diagnostic significance to discover molecular markers for distinguishing the benign from the malignant follicular thyroid tumors, we focused on the 131 known genes. The 24 tumors could also be divided by hierarchical clustering across the 131 known genes into two main groups, all FTAs on one side and all FTCs on the other side (Fig. 1B) . The different gene expression patterns were validated by three-dimensional PCA analysis in the two tumor types (Fig. 2B) . Then, we applied LOOP to perform k-means clustering. Adenomas and carcinomas were always separated on the basis of expression patterns of these genes (data not shown).
The main biological classifications of the differentially expressed genes are composed of signal transduction, transcription and post-transcription regulation, biosynthesis and metabolism, regulators of cell growth and proliferation, nucleic acid binding protein, immuno-response, transport, cell adhesion and extracellular matrix, and integral membrane proteins (Table III) . The first 3 gene categories, i.e., signal transduction, transcription and post-transcription regulation, and biosynthesis and metabolism gene families, accounted for 13, 19 and 23% of the differentially expressed genes, respectively. The majority of these genes were down-regulated in FTC, compared with FTA. Only few genes were frequently up-regulated in FTC.
We then performed permutation analysis of these differentially expressed genes to find out the most significant gene signature with a small number of genes. Permutation analysis revealed 23 genes that can precisely distinguish malignant FTC from benign FTA by means of clustering and Table I . Summary of genes with ≥2-fold alteration in follicular thyroid adenoma and carcinoma. ≥5  947  587  350  620  ≥6  632  403  184  413  ≥8  269  229  42  131  ≥10  17  10  2 
a Number of tumors with ≥2-fold gene change in either FTA or FTC group. Each group has 12 tumors. Table II . Genes with a 2-fold or greater alteration detected in ≥8 tumors of follicular thyroid adenoma or carcinoma group. Table III . Genes differentially expressed between follicular thyroid adenomas and carcinomas.
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Discussion
In this study, we utilized the gene array technology to survey molecular variation of follicular thyroid lesions in an attempt to identify potential molecular markers for the differential diagnosis of FTA and FTC, and to gain new insights into the pathogenesis of the malignant transformation of thyroid lesions. We revealed a set of genes that can precisely distinguish the malignant follicular tumors from the benign ones on the basis of gene expression patterns. Our results Table III . Continued.
Gene symbol Function and description Ca/Ad 
The mean ratio of Ca (follicular thyroid carcinoma) versus Ad (follicular thyroid adenoma). b Student's t-test was used.
strengthen the view that the array technology-based gene expression profiling, when applied to FNA cytology, could certainly help the clinical management of patients with suspicious thyroid lesions. Previous studies have shown that it is possible to determine the level of transcripts by PCR using as few as 10 cells obtained from the FNA biopsy (26) , and that the gene array technique is suitable for preoperative diagnosis of thyroid cancer (27) . Notably, many of the differentially expressed genes identified in this study are related to signal transduction, transcription and post-transcription regulation, and the biosynthesis and metabolism of protein, fat, carbohydrate and nuclear acid. This finding is generally consistent with previous reports (28, 29) , implying that abnormal changes in signaling pathways and/or transcription and post-transcription regulation result in disturbances in the biosynthesis and metabolism of proteins, which in turn impact the metabolisms of other substances such as fat, carbohydrate and nuclear acid. Most of the identified genes have not been reported previously in the context of thyroid malignancies. A further detailed evaluation of these genes would provide important information about the relationship between FTA and FTC and the underlying mechanisms of thyroid malignant transformation.
In our previous cDNA array study on follicular and papillary thyroid cancer (25) , it was shown that the majority of genes with altered expression were involved in both follicular (FTC) and papillary thyroid carcinomas (PTC). Similarly, the results presented here also demonstrates that both FTC and FTA share a majority of genetic alterations. Only a small number of genes were found to be differentially expressed between FTC and PTC or between FTC and FTA. The shared molecular characteristics reflect the close histological and biological relationship of the three types of thyroid tumors, while the differentially expressed genes may contribute to their different cellular appearance and biological behavior.
It is noteworthy that none of these differentially expressed genes were consistently up-or down-regulated in all FTC or all FTA samples and that these genes, only when they are used as a whole, could correctly partition the samples into the histopathology-associated groups. This type of assignment is based on the distinctive expression pattern of a gene signature containing a set of genes, rather than the degree of up or downregulation of any particular gene. This phenomenon is consistent with the knowledge that multiple genetic events are involved in the thyroid tumorigenesis. In theory, an initial slight abnormality of a specific gene could greatly impact other genes in its pathway and result in disturbances in biosynthesis and metabolism of many related proteins, which in turn affect cell regulation, differentiation and growth. The degree of multiple molecular alterations may be much more evident than that of the causative specific gene, making it difficult to identify the causative gene. Therefore, a specific gene, which is found in a univariate study to be associated with thyroid cancer, may not turn out to be the best multivariate factor for predictive and diagnostic purposes. Our results demonstrate that, for the purpose of differential diagnosis of follicular thyroid lesions, individual genes might be less important.
The present study provides a clear example of how gene expression profiling could be highly useful for the diagnosis of thyroid cancer. Several similar studies have been published and different gene signatures described as being useful for distinguishing between the benign and malignant thyroid tumors (18) (19) (20) (21) (22) (23) 29) . Some research groups have even shown that a combination of several genes can be used for this differential diagnostic purpose. For example, Weber et al proposed a three-gene combination (CCND2, PCSK2 and PLAB) as a classifier, since they evaluated the expression level of the 3 genes by real-time PCR from a set of 80 differentially expressed genes they had identified (20) , and Mazzanti et al described a predictor model using 6 or 10 genes selected from 47 genes differentially expressed between FTA and FTC (19) . However, gene signatures reported to date in regard to the differentiation of FTA from FTC, like in other human tumors, differ among different research groups. Although some labs could partly confirm their gene array results by real-time PCR or by using an independent group of test samples, consistent findings have not been obtained by others. This apparent lack of reproducibility, which has been construed as a weakness of genome-wide gene expression data, may arise from the intrinsic properties of different array platforms themselves (30, 31 ). In addition, other possible causes of the discordance in gene expression profiling include: (i) different experimental conditions, e.g., variations in labeling and hybridization, (ii) different procedures in the gene selection, which may lead to the identification of different sets of targets, and (iii) different statistical models for data analysis. The disharmony is a challenge for developing diagnostic and prognostic tools. To eliminate this discordance, international co-operative efforts are required to develop a set of standards and refine these array technologies, which are now in progress.
Nonetheless, our study and other similar ones suggest that gene expression profiling can be used to differentiate a benign from a malignant tumor and therefore is a promising tool in the future for clinical decision making. A combination of the genes identified in this study and the ones detected in other studies might increase the reliability of the differential diagnosis of a follicular thyroid tumor. Clearly, further work is needed to evaluate the different sets of genes identified by different research groups, in order to develop a clinically useful testing system. It is important that such a testing system must be rigorously evaluated using larger data sets to obtain reliable performance estimates. We hope that the results presented here will provide a useful source for developing such a testing system and therefore facilitate differential diagnoses of thyroid nodules to eliminate unnecessary operations for patients with suspicious thyroid lesions.
